Naijun Chen

2.0k total citations · 1 hit paper
46 papers, 1.5k citations indexed

About

Naijun Chen is a scholar working on Epidemiology, Genetics and Surgery. According to data from OpenAlex, Naijun Chen has authored 46 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Epidemiology, 21 papers in Genetics and 14 papers in Surgery. Recurrent topics in Naijun Chen's work include Inflammatory Bowel Disease (21 papers), Microscopic Colitis (20 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). Naijun Chen is often cited by papers focused on Inflammatory Bowel Disease (21 papers), Microscopic Colitis (20 papers) and Rheumatoid Arthritis Research and Therapies (11 papers). Naijun Chen collaborates with scholars based in United States, Germany and United Kingdom. Naijun Chen's co-authors include Jingdong Chao, Andrew Park, Anthony Wang, Inga Peter, Marla Dubinsky, Susan Bressman, Parvez Mulani, Mary Cifaldi, Dennis A. Revicki and Roopal Thakkar and has published in prestigious journals such as Journal of the American Chemical Society, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Naijun Chen

43 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti–Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease

2018 286 citations Naijun Chen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Naijun Chen United States	20	480	442	433	253	226	46	1.5k
Yo Ueda Japan	17	84 0.2×	158 0.4×	147 0.3×	156 0.6×	86 0.4×	96	1.1k
Thomas Lehmann Switzerland	22	265 0.6×	331 0.7×	158 0.4×	147 0.6×	623 2.8×	60	2.2k
Gabriele E. Lang Germany	28	94 0.2×	47 0.1×	142 0.3×	61 0.2×	49 0.2×	140	3.6k
Bettina Heidecker Germany	25	96 0.2×	222 0.5×	269 0.6×	262 1.0×	25 0.1×	84	3.2k
Melissa Wasserstein United States	35	380 0.8×	529 1.2×	354 0.8×	65 0.3×	408 1.8×	93	3.3k
Albert J. Augustin Germany	35	108 0.2×	212 0.5×	258 0.6×	207 0.8×	37 0.2×	180	5.2k
Kentaro Takahashi Japan	30	150 0.3×	197 0.4×	106 0.2×	536 2.1×	59 0.3×	167	2.8k
Shahrad R. Rassekh Canada	25	147 0.3×	114 0.3×	231 0.5×	48 0.2×	96 0.4×	108	2.7k
Yoko Tanaka Japan	23	58 0.1×	198 0.4×	109 0.3×	210 0.8×	109 0.5×	107	1.5k
Shinichi Okada Japan	19	93 0.2×	85 0.2×	93 0.2×	98 0.4×	60 0.3×	85	1.2k

Countries citing papers authored by Naijun Chen

Since Specialization

Citations

This map shows the geographic impact of Naijun Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naijun Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naijun Chen more than expected).

Fields of papers citing papers by Naijun Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naijun Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naijun Chen. The network helps show where Naijun Chen may publish in the future.

Co-authorship network of co-authors of Naijun Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Naijun Chen. A scholar is included among the top collaborators of Naijun Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naijun Chen. Naijun Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kirby, Joslyn S., Siwei Wang, Vishvas Garg, et al.. (2024). Uncovering the burden of hidradenitis suppurativa misdiagnosis and underdiagnosis: a machine learning approach. SHILAP Revista de lepidopterología. 6. 1200400–1200400. 2 indexed citations

Ananthakrishnan, Ashwin N., Raj Desai, Wan‐Ju Lee, et al.. (2023). Economic Burden of Fatigue in Inflammatory Bowel Disease. Crohn s & Colitis 360. 5(3). otad020–otad020. 9 indexed citations

Wu, Jashin J., et al.. (2023). Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States. Journal of Dermatological Treatment. 34(1). 2200869–2200869. 1 indexed citations

Bergman, Martin, Naijun Chen, Richard J. Thielen, & Patrick Zueger. (2023). One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib. Advances in Therapy. 40(10). 4493–4503. 7 indexed citations

Yang, Guojun, et al.. (2023). CTRP13 alleviates palmitic acid-induced inflammation, oxidative stress, apoptosis and endothelial cell dysfunction in HUVECs. Tissue and Cell. 86. 102232–102232. 2 indexed citations

Gao, Qian, et al.. (2022). Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network. Scientific Reports. 12(1). 188–188. 17 indexed citations

Gao, Qian, Wenjun Zhang, Tingting Li, et al.. (2021). The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus. Medicine. 100(7). e24873–e24873. 3 indexed citations

Gao, Qian, et al.. (2021). The efficacy and safety of glucokinase activators for the treatment of type-2 diabetes mellitus. Medicine. 100(40). e27476–e27476. 9 indexed citations

Bergman, Martin, et al.. (2020). Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatology and Therapy. 8(1). 109–118. 28 indexed citations

10.

Bosch, Filip Van den, Andrew J.K. Östör, Siegfried Wassenberg, et al.. (2017). Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study. Rheumatology and Therapy. 4(1). 85–96. 24 indexed citations

11.

Revicki, Dennis A., Arijit Ganguli, Miriam Kimel, et al.. (2015). Reliability and Validity of the Work Instability Scale for Rheumatoid Arthritis. Value in Health. 18(8). 1008–1015. 12 indexed citations

12.

Heijde, Désirée van der, Avani Joshi, Aileen L. Pangan, et al.. (2015). ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis. Lara D. Veeken. 55(1). 80–88. 50 indexed citations

13.

Feagan, Brian G., William J. Sandborn, Andreas Lazar, et al.. (2013). Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis. Gastroenterology. 146(1). 110–118.e3. 76 indexed citations

14.

Colombel, Jean‐Frédéric, Paul Rutgeerts, William J. Sandborn, et al.. (2013). Adalimumab Induces Deep Remission in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology. 12(3). 414–422.e5. 191 indexed citations

15.

Louis, Édouard, Robert Löfberg, Walter Reinisch, et al.. (2012). Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial. Journal of Crohn s and Colitis. 7(1). 34–43. 46 indexed citations

16.

Smolen, Josef S, Désirée van der Heijde, Edward Keystone, et al.. (2012). Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Annals of the Rheumatic Diseases. 72(7). 1156–1162. 55 indexed citations

17.

Strand, Vibeke, Anne M. Rentz, Mary Cifaldi, et al.. (2011). Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. The Journal of Rheumatology. 39(1). 63–72. 58 indexed citations

18.

Maksymowych, Walter P., Katherine Gooch, Maxime Dougados, et al.. (2010). Thresholds of patient‐reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristics. Arthritis Care & Research. 62(6). 826–834. 33 indexed citations

19.

Vollenhoven, Ronald van, Mary Cifaldi, Saurabh Ray, Naijun Chen, & Michael H. Weisman. (2010). Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: Work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. Arthritis Care & Research. 62(2). 226–234. 53 indexed citations

20.

Dougados, Maxime, Michelle P. Luo, Walter P. Maksymowych, et al.. (2008). Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: Data from a randomized controlled trial. Arthritis Care & Research. 59(4). 553–560. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact